Unlike the example VBIV will go down and stay down because there is too much time before anything can happen with the positive prs. Then the pps will move on the PRs.
A desert of PRs always tanks ore revenue biotech.
Frankly, VBIV already did peak and got revived by the Motley article. This will not last long so follow the chart and if it breaks the 50 day MA again, sell.
Market Data 
Markets 
AI
